J. Wood Capital
1820 Calistoga Road, Santa Rosa, California, 95404, United States
Overview
J. Wood Capital Advisors is an advisory firm and registered broker-dealer that focuses on providing capital structure advice and solutions to corporate clients for capital raising.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Advice
- Consulting
- Financial Services
Investment portfolio
- Tisento Therapeutics
Participated · Series A · Aug 2023
Tisento Therapeutics is a Cambridge, MA-based developer of novel medicines targeting diseases with significant unmet needs. The company launched with an $81m Series A financing to advance its pipeline. Tisento acquired zagociguat and CY3018 from Cyclerion; zagociguat is a Phase 2 soluble guanylate cyclase (sGC) stimulator being developed for MELAS and other genetic mitochondrial diseases, while CY3018 is a CNS-targeted sGC stimulator in IND-enabling studies. The company intends to use the funds to develop zagociguat in MELAS and other genetic mitochondrial diseases and to advance additional assets for serious diseases with unmet need. As part of the asset purchase, Cyclerion received 10% equity ownership in Tisento with anti-dilution protection through a $100m post-money valuation and the right to purchase additional equity, and Cyclerion received a $10.4m cash payment (including an $8m upfront payment and reimbursements). In conjunction with the asset sale, Tisento CEO Peter Hecht invested $5m in Cyclerion.
- tisento
Participated · Series A · Jul 2023
Tisento launched with a focused pipeline centered on zagociguat, a first-in-class, brain-penetrant soluble guanylate cyclase (sGC) stimulator that showed promising Phase 2a biomarker and safety data in MELAS. The company plans to advance zagociguat into a Phase 2b study in MELAS and to develop additional assets for serious diseases with unmet need. Tisento acquired zagociguat and CY3018 (a CNS-targeted sGC stimulator in IND-enabling studies) from Cyclerion as part of an asset purchase agreement. The company closed an $81 million Series A to support clinical development and operations and is led by CEO Peter Hecht. Cyclerion received 10% equity in Tisento with anti-dilution protection through a $100 million post-money valuation and a $10.4 million cash payment related to the transaction. Tisento’s investor syndicate includes major Cyclerion shareholders and strategic backers, reflecting support for rapid clinical advancement.
Team
No current team members are available.